Kathy Oubre, MS, chief operating officer, Pontchartrain Cancer Center, explores US adoption of biosimilars ahead of her panel discussion at the 2021 Community Oncology Conference, as well as what sessions she’s looking forward to attending.
Kathy Oubre, MS, is the chief operating officer at Pontchartrain Cancer Center.
Transcript
For the 2021 Community Oncology Conference, a panel will discuss biosimilars in cancer care. Can you speak on the current state of biosimilar uptake in oncology practices and any progress made in recent years?
Oubre: So, US adoption of biosimilars continues to gain traction. According to a recent analysis by Ronny Gal, senior analyst with Bernstein and a presenter at COA this year, in the latter part of 2020, the market reached an annualized savings of approximately $7 billion for the overall US health care system.
In addition, a recent NCCN [National Comprehensive Cancer Network] poster presented showed rapid adoption of the biosimilar Kanjinti during its first year of availability in patients with breast cancer, whether or not they had previously received the originator Herceptin.
These market shifts are likely a combination of patient acceptance, physician confidence, and a growing demand from patients, physicians, and employer groups for payers to include biosimilars on their formularies.
A recent op-ed by Peter Bach argued that we should throw in the towel on biosimilars. I find this to be a rather short-sighted statement. In 2019, former FDA Commissioner Scott Gottlieb, MD, argued that we shouldn't give up on biosimilars and prematurely regulate prices. A review of recent literature over the past year or so supports Dr. Gottlieb's comments. Biosimilar adoption is increasing, competition is accelerating, and prices are dropping.
What sessions or topics at this year’s conference will you be interested to learn more on?
Oubre: I'm most interested to hear Ronny Gal, the senior analyst from Bernstein, who will discuss the hospital transparency requirement that the government started in January. Ronny's research will support what those of us in community oncology have known for years: that hospitals overcharge for drugs. His research will also support that community oncology remains the best high-quality, low-cost provider.
So, on the pharmacy side, the PBM [pharmacy benefit manager] and payer update will be fascinating. And we will have an amazing panel with John Levitt from Frier Levitt, our own Ted Okon, Rich Ingram, MD, and Stuart Genschaw. This session will be sure to highlight the games and tricks that PBMs and insurers play.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More